CAJ | 학술논문

目的：评价复方苦参注射液联合腔内化疗治疗恶性腹水的有效性和安全性。方法分别检索中国期刊全文数据库（CNKI）、万方数据库、维普、中国生物医学文献数据库（CBM）和PUBMED等电子数据库。使用Jadad量表进行文献质量评价，并用Stata 12.0软件进行统计分析。结果共9个随机对照试验纳入分析，纳入试验均为低质量研究。合并结果显示复方苦参注射液联合腔内化疗在控制腹水（RR=1.555，95％CI 1.377~1.756）、改善生活质量（RR=1.574，95％CI 1.352~1.833）、降低胃肠道反应（RR=0.728，95％CI 0.559~0.948）方面优于单用腹腔内化疗。结论复方苦参注射液联合腹腔内化疗治疗恶性腹水可能具有一定的增效减毒作用，进一步明确需要严格规范的随机对照试验来验证。
목적：평개복방고삼주사액연합강내화료치료악성복수적유효성화안전성。방법분별검색중국기간전문수거고（CNKI）、만방수거고、유보、중국생물의학문헌수거고（CBM）화PUBMED등전자수거고。사용Jadad량표진행문헌질량평개，병용Stata 12.0연건진행통계분석。결과공9개수궤대조시험납입분석，납입시험균위저질량연구。합병결과현시복방고삼주사액연합강내화료재공제복수（RR=1.555，95％CI 1.377~1.756）、개선생활질량（RR=1.574，95％CI 1.352~1.833）、강저위장도반응（RR=0.728，95％CI 0.559~0.948）방면우우단용복강내화료。결론복방고삼주사액연합복강내화료치료악성복수가능구유일정적증효감독작용，진일보명학수요엄격규범적수궤대조시험래험증。
Objective To evaluate the efficacy and safety of compound Kushen injection plus intraperitoneal chemo-therapy for patients with malignant ascites. Methods Databases of CNKI, Wanfang, VIP, CBM and PUBMED were searched and the randomized controlled trials (RCTs) on compound Kushen injection plus intraperitoneal chemotherapy for malignant ascites were included. The quality of included studies was assessed by Jadad scoring. Quantitative data synthesis was con-ducted by using the statistical software Stata 12.0. Results Nine RCTs were included in the present meta-analyses. The in-cluded studies were in low quality. Meta-analysis showed that compound Kushen injection plus intraperitoneal chemother-apy could significantly increase the effective rate (RR=1.555, 95%CI 1.377~1.756), improve the quality of life (RR=1.574, 95%CI 1.352~1.833), and decrease the gastrointestinal reactions (RR=0.728, 95%CI 0.559~0.948), as compared with intraperitoneal chemotherapy alone in the treatment of malignant ascites. Conclusion The present meta-analysis indicated that compound Kushen injection plus intraperitoneal chemotherapy could improve the efficacy and quality of life of patients with malignant ascites. More normalized randomized controlled trials were still needed to provide further evidences.